Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered immune cells take on Hard-to-Treat prostate cancer

NCT ID NCT05022849

First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 27 times

Summary

This early-phase study tested a new treatment called JNJ-75229414, which uses a patient's own immune cells (CAR-T cells) to target a protein found on prostate cancer cells. The study involved 15 men with metastatic castration-resistant prostate cancer who had already tried other treatments. The main goals were to find the safest dose and to check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • City of Hope Cancer Center

    Duarte, California, 91010, United States

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Levine Cancer Institute

    Charlotte, North Carolina, 28204, United States

  • Norton Cancer Institute

    Louisville, Kentucky, 40207, United States

  • University Of Minnesota

    Minneapolis, Minnesota, 55455, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • University of Utah Huntsman Cancer Institute

    Salt Lake City, Utah, 84112, United States

Conditions

Explore the condition pages connected to this study.